Learn about the diagnosis and treatment of lupus, a chronic autoimmune condition affecting millions of Americans and individuals globally.

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery ...

The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel.

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...

Lupus, an autoimmune disease affecting at least 5 million people worldwide and disproportionately impacting women, presents daily challenges for 30 to 50 out of every 100,000 individuals in the ...

WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, ...

The withdrawal of immunosuppressants proves noninferior to the withdrawal of glucocorticoids and is safe in patients with ...

Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

系统性红斑狼疮（SLE）患者常需长期服用羟氯喹（HCQ），但其视网膜毒性令人担忧。研究人员运用扫频源光学相干断层扫描血管造影（SS-OCTA）技术开展研究，发现长期 HCQ 治疗会影响 SLE 患者视网膜结构和微循环。这为早期监测 HCQ 视网膜毒性提供了依据。

The analysis of 3 dozen studies found similarities and differences in motivating factors for and against clinical trial ...